Clayton Financial Group’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
Sell
-2,013
Closed -$224K 86
2025
Q1
$224K Sell
2,013
-153
-7% -$16.3K 0.08% 108
2024
Q4
$211K Hold
2,166
0.08% 119
2024
Q3
$249K Buy
+2,166
New +$246K 0.09% 101

Other funds holding NVS

Clayton Financial Group's NVS Position: Q2 2025 in Review

Clayton Financial Group sold out of Novartis (NVS) in Q2 2025, closing a stake of 2,013 shares — an estimated $224K sold.

Clayton Financial Group first reported a position in NVS in Q3 2024 and held it in 3 quarters. The position peaked at $249K in Q3 2024. 1,383 funds tracked by Wall St. Rank hold NVS as of Q2 2025.

  • Clayton Financial Group reported no remaining Novartis position as of Q2 2025 after selling out during the quarter.
  • Clayton Financial Group sold 2,013 Novartis shares in Q2 2025, an estimated $224K.
  • Clayton Financial Group first reported a position in Novartis in Q3 2024 and held it in 3 quarters.
  • Clayton Financial Group's Novartis position peaked at $249K in Q3 2024.
  • 1,383 funds tracked by Wall St. Rank held Novartis as of Q2 2025.

Based on Clayton Financial Group's 13F filing for Q2 2025, filed 14 Jul 2025.